Sato Shino, Hirooka Kazuyuki, Nitta Eri, Ukegawa Kaori, Tsujikawa Akitaka
Department of Ophthalmology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki, Kagawa, 761-0793, Japan.
Adv Ther. 2016 Sep;33(9):1628-34. doi: 10.1007/s12325-016-0389-3. Epub 2016 Jul 20.
The aim of this study is to investigate the additive intraocular pressure (IOP)-lowering effects and safety of the selective Rho kinase inhibitor, 0.4% ripasudil, in patients with glaucoma not adequately controlled by other maximal tolerated medical therapies.
We retrospectively reviewed 92 glaucoma patients who received ripasudil as an additive glaucoma treatment. In spite of receiving prior maximal tolerated medical therapies, all patients had uncontrolled glaucoma before receiving ripasudil. IOP was recorded at all follow-up dates.
The study population consisted of 43 primary open-angle glaucoma (POAG), 28 normal-tension glaucoma (NTG), ten secondary glaucoma, seven exfoliation glaucoma, and four developmental glaucoma patients. After ripasudil administration, there was a significant decrease in the IOP. The mean pre-administration IOP and % IOP reduction at the last follow-up were 19.7 ± 4.9 mmHg and 6.5 ± 17.0% for POAG, 15.5 ± 2.0 mmHg and 2.3 ± 10.4% for NTG, 22.8 ± 8.3 mmHg and 19.1 ± 13.5% for secondary glaucoma, 22.5 ± 4.4 mmHg and 2.1 ± 14.5% for exfoliation glaucoma, and 20.2 ± 8.9 mmHg and 11.4 ± 23.1% for developmental glaucoma, respectively. Side effects led to ripasudil discontinuation in 13 patients, with five exhibiting an allergic reaction, six developing blepharitis, and two having a burning sensation.
Use of ripasudil as an adjunctive therapy resulted in lowering of the IOP. Ripasudil was well tolerated.
Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (26462689).
本研究旨在探讨选择性Rho激酶抑制剂0.4%玻璃酸钠对经其他最大耐受药物治疗后眼压控制不佳的青光眼患者的眼压降低附加效果及安全性。
我们回顾性分析了92例接受玻璃酸钠作为青光眼附加治疗的患者。尽管之前接受了最大耐受药物治疗，但所有患者在接受玻璃酸钠治疗前青光眼均未得到控制。在所有随访日期记录眼压。
研究人群包括43例原发性开角型青光眼（POAG）、28例正常眼压性青光眼（NTG）、10例继发性青光眼、7例剥脱性青光眼和4例发育性青光眼患者。使用玻璃酸钠后，眼压显著降低。POAG患者给药前平均眼压及最后一次随访时眼压降低百分比分别为19.7±4.9mmHg和6.5±17.0%，NTG患者分别为15.5±2.0mmHg和2.3±10.4%，继发性青光眼患者分别为22.8±8.3mmHg和19.1±13.5%，剥脱性青光眼患者分别为22.5±4.4mmHg和2.1±14.5%，发育性青光眼患者分别为20.2±8.9mmHg和11.4±23.1%。副作用导致13例患者停用玻璃酸钠，其中5例出现过敏反应，6例发生睑缘炎，2例有烧灼感。
使用玻璃酸钠作为辅助治疗可降低眼压。玻璃酸钠耐受性良好。
日本文部科学省科研资助金（26462689）。
